NewAmsterdam Shares Positive Alzheimer’s Biomarker Data from Phase III Trial

NewAmsterdam Pharma reported promising Alzheimer’s biomarker findings from a pre-specified sub-study of its Phase III BROADWAY trial evaluating obicetrapib. The study assessed the drug’s impact on plasma biomarkers in all participants, including APOE4 carriers. Conducted across global sites, the 52-week trial involved 2,530 adults with atherosclerotic cardiovascular disease (ASCVD) and/or HeFH, whose LDL-C remained uncontrolled despite intensive lipid-lowering therapy.

Participants received either 10mg obicetrapib or placebo daily. At 84 days, the treatment showed a 33% LDL-C reduction versus placebo. The trial also demonstrated favorable changes in Alzheimer's biomarkers over 12 months. Most subjects had baseline LDL-C around 100 mg/dL and were on high-intensity statins. Obicetrapib, a CETP inhibitor, aims to improve LDL-C control with a side effect profile similar to placebo, as shown in earlier trials.

18-06-2025